Immediate administration of intravesical mitomycin C after tumour resection for superficial bladder cancer

Abstract

OBJECTIVE To assess the feasibility and safety of administering intravesical mitomycin C in theatre immediately after transurethral resection of bladder tumour (TURBT). PATIENTS AND METHODS A protocol was developed to allow the safe administration of mitomycin C in theatre immediately after TURBT. Over a 32‐month period all patients not excluded by the protocol were given mitomycin C in theatre after TURBT, and any adverse events reported. RESULTS In all, 177 instillations were carried out; there were two minor patient‐related complications, and no staff‐related adverse events. CONCLUSION The immediate administration of mitomycin C in theatre after TURBT is feasible and safe for patients and staff. It provides the earliest and surest prophylaxis against tumour cell re‐implantation at TURBT.